NDT 9513727 is negative allosteric modulator (NAM) of C5a receptor (C5aR) with IC50 of 11.6 nM for human C5aR.

BCX 1470 methanesulfonate inhibits the esterolytic activity of factor D (IC50=96 nM) and C1s (IC50=1.6 nM), 3.4- and 200-fold better, respectively, than that of trypsin.

Phaseoloidin是一种从烟草细毛虫中提取的高纯酸苷，具有抗补体活性，并能减少鳞翅目草食动物幼虫的生长，用于植物防御机制研究。

Entadamide-A-β-D-glucopyranoside是从菜豆虫种子中提取的主要成分之一，具有抗补体活性。该化合物在补体系统的研究中展现出调节免疫反应的潜力。

Iptacopan HCl是一种因子 B（ factor B） 抑制剂，能有效抑制补体系统中的因子 B，具有在免疫相关疾病和补体介导疾病中的潜力。

Danicopan is selective and orally active small-molecule factor D inhibitor, shows high binding affinity to human Factor D with Kd value of 0.54 nM. It has potential to block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

EG00229 is the first small molecule inhibitor of the neuropilin-1 and VEGF-A interaction with an IC50 of inhibition of 8 μM(125I-VEGF binding to PAE/NRP1 cells).

SB290157 trifluoroacetate是一种高效且选择性的C3a受体拮抗剂，IC50为200 nM。

PMX 53 is a potent C5a receptor antagonist.

Iptacopan是一种首创的、高效的、口服活性的factor B抑制剂，IC₅₀为10 nM，KD值为7.9 nM。该化合物通过直接且可逆地结合factor B，靶向C3肾小球病的根本病因，具有治疗此类疾病的巨大潜力。

JR14a is a novel potent and selective antagonist of human Complement C3a receptor.

AMY-101 TFA是一种强效的补体 C3 抑制剂 (Kd = 0.5 nM)，用于多种免疫和炎症相关的研究，已显示对非人类灵长类动物的牙周炎及 COVID-19 重症肺炎模型中的抗炎作用。

AMY 101 is a peptidic central complement component C3 inhibitor with Kd value of 0.5nM. It is now in phase 2 study of Gingivitis, Periodontitis and SARS-CoV-2 acute respiratory disease.

Eculizumab是一种人源化IgG2/4单克隆抗体，通过与C5结合来阻止其激活补体系统。Eculizumab具有用于阵发性夜间血红蛋白尿症和非典型溶血性尿毒症综合征研究的潜力。